PetCure marks 10,000 radiation therapy patients treated

PetCure Oncology says it has now treated 10,000 pets with radiation therapy since launching in 2015, a milestone the company is framing as evidence that advanced radiation oncology has moved beyond a handful of academic centers and into broader specialty practice. In its January 7 announcement, the Thrive Pet Healthcare-affiliated group said its model was built to expand access to stereotactic radiation therapy, which can often be delivered in one to three fractions instead of longer conventional protocols. The company’s growth comes as PetCure marks 10 years in operation and continues to expand its footprint and technology partnerships, including a late-2025 deal with Empyrean Medical Systems to bring a new Sirius radiation platform to Seattle in early 2026. (petcureoncology.com)

Why it matters: For veterinary professionals, the bigger story is access. PetCure’s own materials say that when the company launched, fewer than 70 traditional veterinary radiation therapy facilities existed in the U.S., with fewer than 10 offering stereotactic radiosurgery or radiotherapy. More recent industry and professional sources suggest the field has broadened, with boarded veterinary radiation oncologists now practicing across more than 30 states and radiation facilities listed well beyond academia. That doesn’t mean access problems are solved, but it does suggest referral pathways for oncology, palliative care, and low-dose radiation applications are more realistic than they were a decade ago, especially for practices tied to multispecialty networks. (petcureoncology.com)

What to watch: Watch whether PetCure’s next phase is defined less by milestone counts and more by new platform rollouts, regional expansion, and evidence generation around shorter-course, multidisciplinary radiation oncology care. (empyreanmed.com)